Michael Berry
Chief Tech/Sci/R&D Officer presso EVEREST MEDICINES LIMITED
Profilo
Michael Berry is currently the Chief Technology Officer at Everest Medicines Ltd.
He previously worked as the Senior Director of Bioprocess Development at Portola Pharmaceuticals, Director at ARCA biopharma, Director of Manufacturing Sciences & Technology at Novartis Vaccines & Diagnostics SL, and Vice President at Dynavax Technologies Corp.
He is also the Chief Technical Operations Officer at Clover Biopharmaceuticals Ltd.
Berry received his undergraduate degree from De Montfort University, his graduate degree from The University of Manchester, and his doctorate from the University of Manitoba.
Posizioni attive di Michael Berry
| Società | Posizione | Inizio |
|---|---|---|
| EVEREST MEDICINES LIMITED | Chief Tech/Sci/R&D Officer | 15/06/2023 |
Precedenti posizioni note di Michael Berry
| Società | Posizione | Fine |
|---|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Corporate Officer/Principal | 01/08/2017 |
| PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/02/2015 |
| Novartis Vaccines & Diagnostics SL | Corporate Officer/Principal | 01/09/2013 |
| ARCA BIOPHARMA, INC. | Director/Board Member | 01/05/2009 |
| CLOVER BIOPHARMACEUTICALS, LTD. | Chief Tech/Sci/R&D Officer | - |
Formazione di Michael Berry
| The University of Manchester | Graduate Degree |
| University of Manitoba | Doctorate Degree |
| De Montfort University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
| ARCA BIOPHARMA, INC. | Health Technology |
| EVEREST MEDICINES LIMITED | Health Technology |
| CLOVER BIOPHARMACEUTICALS, LTD. | Health Technology |
| Aziende private | 2 |
|---|---|
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
| Novartis Vaccines & Diagnostics SL |
- Borsa valori
- Insiders
- Michael Berry
